导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.96% | 1466/4773 |
| 近一周 | 0.76% | 80/5462 |
| 近一月 | 5.66% | 52/5421 |
| 近一季 | 5.45% | 269/5209 |
| 近半年 | 6.57% | 676/4920 |
| 近一年 | 4.01% | 1815/4366 |
| 近两年 | 41.17% | 1830/2954 |
| 近三年 | 50.13% | 535/2253 |
| 成立以来 | 85.63% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.76% 2894/4961 |
-7.91% 3813/5312 |
- - |
- - |
| 2025 | 10.79% 2787/4813 |
2.56% 1338/3635 |
11.58% 157/4076 |
-8.39% 4033/4524 |
5.69% 409/4813 |
| 2024 | 39.68% 20/3463 |
9.98% 89/2808 |
6.87% 118/3014 |
12.48% 2333/3129 |
5.65% 579/3463 |
| 2023 | -2.26% 567/2656 |
-2.49% 1995/2280 |
2.07% 172/2385 |
4.89% 114/2515 |
-6.37% 1741/2655 |
| 2022 | -4.07% 79/2207 |
2.22% 69/1919 |
-1.31% 1703/2016 |
-7.97% 156/2113 |
3.33% 716/2208 |
| 2021 | 0.65% 709/1822 |
10.30% 42/1255 |
-2.00% 1187/1330 |
-6.47% 936/1466 |
-0.45% 1241/1822 |
| 2020 | 4.76% 889/1250 |
-12.94% 907/1022 |
2.41% 970/1060 |
6.73% 811/1152 |
- - |
| 2019 | 31.10% 476/1092 |
15.55% 682/748 |
2.71% 70/797 |
2.84% 282/844 |
7.42% 432/912 |
| 2018 | -11.54% 77/834 |
- - |
- - |
- - |
-8.97% 112/691 |
| 2017 | 18.89% 204/714 |
- - |
- - |
- - |
- - |
| 2016 | 0.57% 102/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 招商中证银行指数A VS. 长安沪深300非周期A(740101) |